Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental shingles vaccines CRV-101 and Gla
The FDA has approved GlaxoSmithKline's shingles vaccine Shingrix for use in people aged under 50 who are immunocompromised – a key step in the UK drugmaker's plan to build the shot into a £
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
